Endo International PLC

Endo International — UBS Global Healthcare Conference 2014

22 slides from Endo International's conference presentation, May 21, 2014

  1. Slide 1: Endo at UBS Global Healthcare Conference, May 21, 2014

    Slide 1: Endo at UBS Global Healthcare Conference, May 21, 2014

    Exhibit 99.1 Endo21, UBS May ©2014 Global International Endo 2014Healthcare Pharmaceuticals plc Conference Inc. All rights reserved.

  2. Slide 2: Forward Looking Statements; Non-GAAP Financial Measures

    Slide 2: Forward Looking Statements; Non-GAAP Financial Measures

    Forward “expects,” views, reasonable described applicable, could looking assumes This from in 1©2014 thispresentation non-GAAP affect presentation. expectations Endo statements no Looking in“anticipates,” assumptions with obligation Endo’s the Pharmaceuticals documents the financial contains may Sta

  3. Slide 3: Today's Agenda

    Slide 3: Today's Agenda

    §Today’s ©2014 2Q&A Company Core M&A Near 2014 Term Business Financial Endo Program Agenda Strategy Objectives Pharmaceuticals Growth Guidance andand First Progress Inc. YearAll Progress rights reserved.

  4. Slide 4: Endo's Focus: Build a leading specialty healthcare company

    Slide 4: Endo's Focus: Build a leading specialty healthcare company

    Endo’s Build Focus Participate Transform Continue Maximize and 3@2014 customer aon strategic leading Endo maximizing our shareholder operating in commitment Pharmaceuticals specialty changes global direction model the specialty value areas value totoby offering serving maximize Inc. of adapting heal

  5. Slide 5: Endo Operating Model: Lean, Focused, Streamlined

    Slide 5: Endo Operating Model: Lean, Focused, Streamlined

    Endo Operating Lean, Performance M&A Agnostic Focused, Streamlined 4©2014efficient an Endo important de-risked on and therapeutic metrics Pharmaceuticals operating Model diversified R&D component aligned areas, model organization with Inc. but of building shareholder with All rights focus with &rese

  6. Slide 6: Delivering on Strategy: Year in Review

    Slide 6: Delivering on Strategy: Year in Review

    § Agreements Delivering 5©2014 Announced Strengthened Implemented Completed/initiated Closed Increased Completed Sharpened Enhanced Endo Boca Our on strategic capital R&D Pharmaceuticals the acquisition our inPharmacal, atalent Strategy principle divestiture Lean financial focus structure focus and

  7. Slide 7: Q1 2014 Financial Results

    Slide 7: Q1 2014 Financial Results

    Q1of2014 ($M Favorable Revenues Gross Operating % Tax Adjusted Reported 6©2014 Rate except Revenues Margin Endo Income (Continuing Net EPS Diluted (GAAP) $658 / (Unfavorable) Expenses Income Shares Pharmaceuticals Income $449 $1.09 68.2% 36.3% 31.9% $595 Statement Shares $210 EPS and $399 $239 $0.92

  8. Slide 8: Drive Core Organic Growth: Branded Pharmaceuticals

    Slide 8: Drive Core Organic Growth: Branded Pharmaceuticals

    Drive §Core Announced 7©2014 Managing Launched BEMA® Excludes Organic EndoBuprenorphine acquisition AVEED® successfully Pharmaceuticals Growth Lidoderm®, in –ofU.S. March; through Sumavel® development Actavis Branded Inc.leading Lidoderm® All Royalty DosePro® rights Pharmaceuticals meeting indicator

  9. Slide 9: Drive Core Organic Growth: U.S. Generics

    Slide 9: Drive Core Organic Growth: U.S. Generics

    Drive U.S. §Revenue Continued 8©2014 Successful Strong Conversion Generics Organic Endo prescription Growth strong Integration Pharmaceuticals ofGrowth high-dose double volumes – of U.S. digit APAP Boca Generic Inc. growth growth Pharmacal products All in rights Pharmaceuticals controlled toreserved

  10. Slide 10: Drive Core Organic Growth: Devices

    Slide 10: Drive Core Organic Growth: Devices

    Drive §Devices Accelerated 9©2014 VersusContinued Strong Solid Managing Organic Endo growth Revenue growth process impact Pharmaceuticals Growth ininGrowth International BPH strength of remediation market – business Devices in decline Inc. Men’s plan led AllHealth by underway in rights Women’s incre

  11. Slide 11: Drive Core Organic Growth: International Pharmaceuticals

    Slide 11: Drive Core Organic Growth: International Pharmaceuticals

    §Drive In ©2014 10March Established Supports Key Continuing Progress licensing Organic functions Endo 2014 in ability projects Pharmaceuticals Paladin to Irish performance Growth optimize in-place toTrading (e.g., complete business – International and corporate ZertaneTM Company on-track actively In

  12. Slide 12: Our Committed M&A Strategy

    Slide 12: Our Committed M&A Strategy

    §Our Committed ©2014 11Therapeutically Focused Rigorous Deal-related Positioned M&A Endo on Strategy evaluation toto Pharmaceuticals near-term asynergies evaluate flexible agnostic, governed accretive, capital global primarily butInc. opportunities focused structure byvalue All from keyrights on fin

  13. Slide 13: Recent M&A Progress: Sumavel DosePro Acquisition

    Slide 13: Recent M&A Progress: Sumavel DosePro Acquisition

    §Recent Announced ©2014 12Sumavel Logical Potential Endo M&AfitDosePro toclose with Pharmaceuticals add Progress of existing value expands acquisition –through Sumavel® U.S. portfolio Inc. Branded on greater All May DosePro® rights offocus 19, Pharmaceuticals branded 2014. reserved. pharmaceuticals

  14. Slide 14: Recent M&A Progress: Grupo Farmaceutico Somar Acquisition

    Slide 14: Recent M&A Progress: Grupo Farmaceutico Somar Acquisition

    §Recent 13 Access Acquisition Creates Builds ©2014M&A on Endo to new high starting Progress expected Latin Pharmaceuticals growth point America –toemerging Grupo of close Paladin platform in Farmaceutico Inc. Q3 markets, All in2014 Mexico rights sales Somar reserved. and marketing, R&D and manufactu

  15. Slide 15: Near-Term Financial Priorities

    Slide 15: Near-Term Financial Priorities

    Near-Term Meet Drive Establish Implement Complete Increase Maximize Develop Enhance ©2014 14 Financial Organic Endo Value Organization Continued New 2-3 Balance Lean Priorities Pharmaceuticals Near-term Growth Corporate of Targets Operating Pipeline Sheet Focus and Through Accretive, Flexibility Str

  16. Slide 16: 2014 Financial Guidance

    Slide 16: 2014 Financial Guidance

    2014 Financial Measure Revenues Reported Adjusted Weighted ©2014 15 Endo 2014 Gross Operating Interest Diluted Effective (GAAP) Average $2.55B Pharmaceuticals Guidance Guidance Margin Expenses EPS -Earnings Diluted Tax $2.64B Expenses $3.60 Rate 63%Shares ~$205M (Loss) 23% to toYear-over-year Inc. $

  17. Slide 17: Summary: Wrap-up

    Slide 17: Summary: Wrap-up

    §Summary Recently ©2014 16Executing Reducing Convertible Mesh LIDODERM® Deploying Sale Boca Grupo Enhancing Sharpening Meeting of Endo Pharmacal, liability Farmaceutico raised HealthTronics Wrap-up our impact strategy capital operational Pharmaceuticals R&D Notes Financial 2014 loss Paladin of focus

  18. Slide 18: Appendix

    Slide 18: Appendix

    ©2014 Endo Pharmaceuticals Inc. All rights reserved. Appendix

  19. Slide 19: Reconciliation Notes

    Slide 19: Reconciliation Notes

    Reconciliation Notes REVENUES (3) EXPENSE, INCOME NET ATTRIBUTABLE $0.93 1. 2. defense 3. 4. 5. 6. 7. 8. To ©2014 18 To exclude 31,604 OF exclude reflect Discontinued toEndo costs reconciliation TAX TAX Litigation-related certain NET the Pharmaceuticals $594,609 of amortization certain milestone acq

  20. Slide 20: Reconciliation Notes: Three Months Ended March 31, 2013

    Slide 20: Reconciliation Notes: Three Months Ended March 31, 2013

    Reconciliation Notes Three Selling, (5) 11,312 45,808 $134,492 DATA (0.05) $44,736. litigation-related 3. 4. 5. 6. 7. 8. restatement 9. 10. To ©2014 19 To exclude — Toexclude Months to Acquisition-related (0.01) ATTRIBUTABLE reflect (11,312)(8) INCOME Endo general reconciliation 2.Less: certain To o

  21. Slide 21: Reconciliation for Projected Diluted Earnings Per Share

    Slide 21: Reconciliation for Projected Diluted Earnings Per Share

    For Reconciliation Lower Projected Upfront Amortization Acquisition Basic Charges Interest Tax Diluted •The 20 Certain Includes ©2014 an effect company’s toexplanation End expense adjusted and Diluted for Endo of GAAP all ofof the Related, Litigation milestone-related pre-tax completed of Range Phar

  22. Slide 22: Endo at UBS Global Healthcare Conference, May 21, 2014

    Slide 22: Endo at UBS Global Healthcare Conference, May 21, 2014

    Endo21, UBS May ©2014 Global International Endo 2014Healthcare Pharmaceuticals plc Conference Inc. All rights reserved.

Source: SEC EDGAR · 8-K filed May 21, 2014

More decks from Endo International PLC